Harith Rajagopalan Sells 90,972 Shares of Fractyl Health, Inc. (NASDAQ:GUTS) Stock

Fractyl Health, Inc. (NASDAQ:GUTS) CEO Harith Rajagopalan sold 90,972 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $1.82, for a total transaction of $165,569.04. Following the sale, the chief executive officer now directly owns 491,329 shares in the company, valued at approximately $894,218.78. The trade was a 15.62 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Harith Rajagopalan also recently made the following trade(s):

• On Monday, November 11th, Harith Rajagopalan sold 96,517 shares of Fractyl Health stock. The shares were sold at an average price of $2.47, for a total transaction of $238,396.99.

Fractyl Health Trading Up 7.2 %

GUTS opened at $1.64 on Thursday. The company has a quick ratio of 5.57, a current ratio of 5.58 and a debt-to-equity ratio of 0.60. Fractyl Health, Inc. has a 52 week low of $1.52 and a 52 week high of $11.55. The business’s 50 day moving average is $2.03 and its two-hundred day moving average is $2.47. The firm has a market cap of $78.88 million and a price-to-earnings ratio of -0.13.

Fractyl Health (NASDAQ:GUTS) last announced its earnings results on Tuesday, November 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.02. The business had revenue of $0.01 million for the quarter. On average, research analysts predict that Fractyl Health, Inc. will post -1.66 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Massachusetts Financial Services Co. MA boosted its stake in shares of Fractyl Health by 4.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,045,672 shares of the company’s stock worth $2,646,000 after buying an additional 49,289 shares during the period. Geode Capital Management LLC raised its stake in Fractyl Health by 166.5% during the 3rd quarter. Geode Capital Management LLC now owns 501,476 shares of the company’s stock valued at $1,269,000 after acquiring an additional 313,335 shares during the last quarter. State Street Corp lifted its position in Fractyl Health by 129.4% during the 3rd quarter. State Street Corp now owns 113,415 shares of the company’s stock worth $287,000 after acquiring an additional 63,968 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Fractyl Health by 56.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 80,664 shares of the company’s stock valued at $204,000 after purchasing an additional 29,262 shares during the last quarter. Finally, Conservest Capital Advisors Inc. acquired a new position in shares of Fractyl Health in the fourth quarter valued at approximately $132,000.

Analyst Ratings Changes

Separately, Morgan Stanley reduced their price target on shares of Fractyl Health from $18.00 to $10.00 and set an “overweight” rating for the company in a research report on Monday.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.